-
Sector Analysis
Spain Solar Photovoltaic (PV) Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
Spain Solar Photovoltaic (PV) Market Overview The cumulative installed capacity for solar PV in Spain was 29.97MW in 2022 and will achieve a CAGR of more than 15% during 2022-2035. In 2022, asset transactions deal type closed the majority of deals in Spain's solar photovoltaic market. Spain Solar PV Market Outlook, 2022-2035 Buy the Full Report for More Information on the Spain's Solar PV Market Forecast Download a Free Report Sample The report discusses the cumulative installed capacity, annual capacity addition,...
-
Sector Analysis
Spain Wind Power Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
Spain Wind Power Market Report Overview The cumulative installed capacity for wind power in Spain was 30.18 GW in 2022 and will achieve a CAGR of more than 6% during 2022-2035. The following are some of the key highlights of the Spain wind power market: Rising levels of pollution, fear of global warming, scarcity of fossil fuels, and increasing levels of Greenhouse Gas (GHG) emissions have led many countries to opt for clean renewable energy sources. In Spain’s renewable power...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s ODM-208
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ribociclib Succinate in Oligodendroglioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ribociclib Succinate in Oligodendroglioma Drug Details: Ribociclib succinate (Kisqali, Kryxana) is an antineoplastic agent. It...
-
Product Insights
Galicia Wind Farm-EDP, Spain
Galicia Wind Farm-EDP is proposed to be built in Galicia, Spain. The project is at the permitting stage. Empower your strategies with our Galicia Wind Farm-EDP report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons...
-
Product Insights
NewNet Present Value Model: Verrica Pharmaceuticals Inc’s Ycanth
Empower your strategies with our Net Present Value Model: Verrica Pharmaceuticals Inc's Ycanth report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Ocugen Inc’s OCU-400
Empower your strategies with our Net Present Value Model: Ocugen Inc's OCU-400 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Evelo Biosciences Inc’s EDP-1815
Empower your strategies with our Net Present Value Model: Evelo Biosciences Inc's EDP-1815 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EDP-305 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EDP-305 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: EDP-305 is under development for the treatment...
-
Product Insights
NewNet Present Value Model: Enanta Pharmaceuticals Inc’s EDP-305
Empower your strategies with our Net Present Value Model: Enanta Pharmaceuticals Inc's EDP-305 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.